CIAM
ELVN icon

Caitong International Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Caitong International Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.7K Buy
+980
New +$41.6K 0.01% 720
2026
Q1 		– Sell
-940
Closed -$14.5K – 2715
2025
Q4 		$14.5K Buy
940
+932
+11,650% +$18.6K ﹤0.01% 1067
2025
Q3 		$164 Buy
+8
New +$161 ﹤0.01% 1694
2025
Q2 		– Sell
-215
Closed -$4.23K – 2131
2025
Q1 		$4.23K Buy
215
+205
+2,050% +$4.41K ﹤0.01% 1067
2024
Q4 		$225 Buy
+10
New +$259 ﹤0.01% 1573

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Caitong International Asset Management's ELVN Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 980 shares worth $49.7K. The stake represents 0.01% of the portfolio and ranks #720 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in ELVN as recently as Q4 2025.

Caitong International Asset Management first reported a position in ELVN in Q4 2024 and has held it in 5 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Caitong International Asset Management held 980 shares of Enliven Therapeutics worth $49.7K as of Q2 2026.
  • Enliven Therapeutics was a new Caitong International Asset Management position in Q2 2026.
  • Enliven Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #720 holding.
  • Caitong International Asset Management first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.